Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives

by Nima Rezaei (Editor), Mahsa Keshavarz-Fathi (Editor)

Overview

Therapeutic cancer vaccines represent a type of active cancer immunotherapy. Clinicians, scientists, and researchers working on cancer treatment require evidence-based and up-to-date resources relating to therapeutic cancer vaccines. Vaccines for Cancer Immunotherapy provides a reference for cancer treatment for clinicians and presents a well-organized resource for determining high-potential research areas. The book considers that this promising modality can be made more feasible as a treatment for cancer. Chapters cover cancer immunology, general approaches to cancer immunotherapy, vaccines, tumor antigens, the strategy of allogeneic and autologous cancer vaccines, personalized vaccines, whole-tumor antigen vaccines, protein and peptide vaccines, dendritic cell vaccines, genetic vaccines, candidate cancers for vaccination, obstacles to developing therapeutic cancer vaccines, combination therapy, future perspectives and concluding remarks on therapeutic cancer vaccines.

• Introduces the feasible immunotherapeutic vaccines for patients with different types of cancer
• Presents the status of past and current vaccines for cancer treatment
• Considers advantages and disadvantages of different therapeutic cancer vaccines
• Looks at the combination of vaccines and other modalities, including immunotherapeutic and conventional methods
• Analyzes obstacles to development of therapeutic cancer vaccines
• Gives a view on future perspectives in the application of therapeutic cancer vaccines

Product Details

ISBN-13:	9780128140406
Publisher:	Elsevier Science
Publication date:	10/17/2018
Sold by:	Barnes & Noble
Format:	eBook
Pages:	198
File size:	6 MB

About the Author

Professor Nima Rezaei gained his medical degree (MD) from Tehran University of Medical Sciences and subsequently obtained an MSc in Molecular and Genetic Medicine and a PhD in Clinical Immunology and Human Genetics from the University of Sheffield, UK. He also spent a short-term fellowship of Pediatric Clinical Immunology and Bone Marrow Transplantation in the Newcastle General Hospital. Professor Rezaei is now the Full Professor of Immunology and Vice Dean of Research, School of Medicine, Tehran University of Medical Sciences, and the co-founder and Head of the Research Center for Immunodeficiencies. He is also the founding President of the Universal Scientific Education and Research Network (USERN). Professor Rezaei has already been the Director of more than 55 research projects and has designed and participated in several international collaborative projects. Professor Rezaei is an editorial assistant or board member for more than 30 international journals. He has edited more than 35 international books, has presented more than 500 lectures/posters in congresses/meetings, and has published more than 1,000 scientific papers in the international journals.
Mahsa Keshavarz-Fathi is a medical researcher and MD candidate at Tehran University of Medical Sciences (TUMS). She is also the managing director of the Cancer Immunology Project (CIP) and Breast Cancer Association (BrCA) undertaking and managing different research projects in the field of cancer treatment, cancer immunology and immunotherapy.

Table of Contents

1. Cancer immunology 2. Immunotherapeutic Approaches in Cancer 3. Vaccines, Adjuvants, and Delivery Systems 4. Tumor Antigens 5. Strategy of Allogeneic and Autologous Cancer Vaccines 6. Personalized Cancer Vaccine 7. Whole Tumor Cell Vaccine for Cancer 8. Peptide and Protein Vaccines for Cancer 9. Immune Cell Vaccine for Cancer 10. Genetic Vaccine for Cancer 11. Candidate Cancers for Vaccination 12. Obstacles in the Development of Therapeutic Cancer Vaccines 13. Combination Therapy: Cancer Vaccines and Other Therapeutics 14. Concluding Remarks and Future Perspectives on Therapeutic Cancer Vaccines

What People are Saying About This

From the Publisher

Provides an evidence-based coverage of vaccines for cancer immunotherapy